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Abstract Mucopolysaccharidosis type VI (Maroteaux–Lamy
syndrome, MPS VI, OMIM 253200) is caused by mutations
in the gene coding for N-acetylgalactosamine-4-sulfatase (4-
sulfatase, arylsulfatase B, ARSB, EC 3.1.6.12), a lysosomal
enzyme involved in the degradation of dermatan sulfate (DS).
The clinical presentation of MPS VI varies greatly with re-
spect to age of onset and rate of disease progression. This
report focuses on the attenuated form of MPS VI, which can
go unrecognized for years and often presents with atypical
signs or symptoms. We described a cohort of MPS VI patients
(n =4) heterozygous for the p.Y210C mutation who had a
significant osteoarticular involvement at the onset of their
disease and who were diagnosed years or even decades later.
We have also reviewed the literature (n =36). Two types of
attenuated MPS VI phenotypes could be distinguished:
osteoarticular and cardiac. The majority of MPS VI patients
reported so far as relatively attenuated presented with an
essentially osteoarticular phenotype associated with the
p.Y210C mutation. Patients homozygous for the p.R152W
mutation presented with a cardiac phenotype, which, despite
fulfilling the generally used criteria for attenuated phenotype,
may lead to fast disease progression and abrupt death. The
knowledge of natural history and genotype–phenotype corre-
lation may help in developing a tailored therapy potentially
using enzyme replacement therapy with substrate reduction
therapy or chaperones.
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Introduction
Mucopolysaccharidosis type VI (Maroteaux–Lamy syn-
drome, MPS VI, OMIM 253200) is an inherited metabolic
d i s e a s e c aus ed by a de f i c i en t a c t i v i t y o f N -
acetylgalactosamine-4-sulfatase (4-sulfatase, arylsulfatase B,
ARSB, EC 3.1.6.12), a lysosomal enzyme involved in the
degradation of dermatan sulfate (DS) [1, 2]. The clinical
presentation of MPS VI varies greatly with respect to age of
onset and rate of disease progression. Descriptive classifica-
tion systems have described patients’ phenotypes as severe
(with early onset of symptoms and fast progression), attenu-
ated (with later onset, slower disease progression, and variable
clinical presentation), and intermediate [1, 3]. Especially in
attenuated phenotypes, a definite diagnosis may be delayed
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for years because early symptoms are difficult to recognize for
physicians not familiar with the disease, since the disease
progresses silently over decades.
The incidence rates for this rare disease vary in the litera-
ture between 0.05 [4] and 2.3 [5] diagnosed MPS VI patients
per 100,000 live births. Allele frequencies of the different
mutations are very low, and most mutations are unique to
individual families, except for a high prevalence of
p.R152W mutation in Eastern European population [6].
This report focuses on the less severe form ofMPS VI. The
objective of this article is to show the existence of significant
differences between so-called attenuated patients and to high-
light the need of close cooperation of different specialties in
order to recognize the disease early. The knowledge of natural
history and genotype–phenotype correlation may also help in
developing a tailored therapy.
Patients and methods
Patient enrollment and data collection
The lists of diagnosed MPS VI patients were provided by
seven diagnostic centers for MPS VI in Central and Eastern
Europe (Warsaw, Prague, Vilnius, Minsk, Riga), Russia
(Moscow), and Kazakhstan (Almaty). Out of these patients,
only patients with the less severe form of MPS VI were
included in our study.
All patients were naïve to enzyme replacement therapy
(ERT) at the time of the study.
Ethical consideration
The protocol was approved by the Human Subjects Institu-
tional Review Board at the Children’s Memorial Health Insti-
tute. Written informed consent had to be provided by the
parents or legal guardians. All patients and/or their families
provided written consents about using their photos.
Results
Patient population
The main demographic and clinical characteristics of all pa-
tients in our series are shown in Table 1. All of the patients
were Caucasian, and no sex predominance was seen. No
consanguinity between parents was recorded.
First clinical features and disease progression
For all four patients, the age of first symptom onset ranged
from 5 to 8 years (median 8 years). The most common first
sign to appear was decreased joint range of motion of large
joints of the upper and/or lower limbs. The most commonly
affected joints were hips, which resulted in hip pain with
difficulty in walking and stair climbing. The first misdiagno-
ses in these patients were Perthes disease, hip dysplasia or
osteochondrosis. In addition to the joint problems, some of the
patient cohort reported features such as recurrent rhinitis,
impaired hearing, hydrocephalus, and in the case of older
patients, spinal cord compression.
Within the disease course, the patients developed
other disease manifestations such as skeletal abnormali-
ties (Figs. 1 and 2), growth retardation, and spinal cord
compression.
Joint stiffness was reported in all patients. It was located
mainly in the shoulder and hip joints or other large joints of the
upper and/or lower limbs. It was intense and significantly
impaired the quality of the patient’s life leading to consulta-
tions by orthopedic surgeons. Typical for MPS contractures of
fingers (so-called claw hands) were also observed decreasing
the function, efficiency, and skills of the hands.
At the time of the study, the eldest patients were 45 and
40 years of age.
Delayed diagnosis
Following the onset of signs and symptoms, MPS VI diagno-
sis occurred after 9 years of age (range 9–45 years, median
24 years) with median delays 17.5 years.
Literature review
Clinical phenotypes
The results of the literature review are presented in Table 2,
which includes only reports with clinical data (n =36). The
review of the literature allowed distinguishing two types of
attenuated MPS VI phenotypes: osteoarticular and cardiac.
In a majority of reported patients, a relatively attenuated
phenotype meant an essentially osteoarticular phenotype.
These patients initially presented with bone and joint symp-
toms, especially pain and stiffness in the joints, joint contrac-
tures, and hip and back pain. At some point, most of these
patients developed serious manifestations of the disease in-
cluding joint degeneration, sleep apnea, a decrease in pulmo-
nary function, reduced endurance, cardiac valve disease, and
skeletal complications including carpal tunnel syndrome and
hip disease.
Unlike the majority of reviewed patients, patients homozy-
gous for p.R152W mutation showed a significantly different
clinical phenotype with predominance of cardiovascular man-
ifestations [7, 8].
726 Clin Rheumatol (2014) 33:725–731
Genotype–phenotype correlation
Mutations associated with an attenuated MPS VI phenotype
are presented in Table 3.
Apart from the p.R152W and p.Y210C mutations, other
mutations have been reported as associated with attenuated
disease progression: p.C192R [9] when present in homozy-
gous state and p.D83Y [10], p.C405Y [10], and p.R434I [10]
when present in compound heterozygous states.
Osteoarticular attenuated phenotype is predominantly associ-
ated with a missense mutation p.Y210C, while cardiac with
p.R152W in homozygosity. So far, only one patient homozy-
gous for p.Y210C mutation has been described in the litera-
ture, while in the majority of patients, this mutation is present
with other mis- or nonsense mutation [11].
Discussion
One of the first descriptions ofmucopolysaccharidosis typeVI
was probably by the neurologist Nonne [12]. After several
investigators indicated heterogeneity of MPS VI based on
radiological findings, the patients’ size, and longevity [13,
14], McKusick suggested separating a severe form
(mucopolysaccharidosis type VIA) from a mild variant (type
VIB) [15]. Based on McKusick’s classification, the longevity,
size, lack of cardiac insufficiency in association with mild
cardiac murmurs, lack of abnormality of sella turcica, and
the absence of umbilical or inguinal hernia, marked
hepatosplenomegaly, and marked corneal opacities warranted
the diagnosis of the mild B variant of MPS VI [15]. Apart
from severe and attenuated phenotypes, descriptive























1 (Czech Republic, 47) 10/45 DW, HP,
JS, RR
CFF, GR, SK Hip dysplasia,
Perthes disease








CFF, HC, SCC 7.4 p.Y210C/
p.C521Y




4 (Russia, 20) 5/10 JS, RR, IH No No CFF, HC 9.8 p.N262Kfs*
14/p.Y210C
DW difficulty in walking,CFF coarse facial features,CH claw hands,GR growth retardation,HC hydrocephalus,HP hip pain, IH impaired hearing, JS
joint stiffness, M myelopathy, RR recurrent rhinitis, SCC spinal cord compression, SK skeletal abnormalities, UH umbilical hernia
a ARSB activity in the patients’ leukocytes was referred to the mean value of several controls analyzed in the same experiment
b NCBI reference sequence: NM_000046.3 (cDNA considering A of the ATG translation initiation codon as nucleotide +1); NP_000037
Fig. 1 a , b Radiographs of a
patient heterozygous for the
p.Y210C mutation. Lateral
radiographs of cervical spine: (1)
reduction of cervical lordosis, (2)
narrowing of L3 vertebral body
and dislocation of L4 vertebral
body (arrows), and (3) thickening
of the skull bones
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classification systems have also described an intermediate
disease form. Other authors suggested other classification
systems based on height and urinary glycosaminoglycan
(uGAG) levels, the age at the onset of symptoms, patient’s
height, and the age of death [16, 17]. In reality, there are no
fixed parameters to ascribe a particular patient to a single
category, and the decision is subjective depending on physi-
cian’s experience and knowledge. The relatively attenuated
disease form is generally characterized by later onset of symp-
toms which may not at first appear in a recognized pattern, but
when apparent, the milder symptoms may be observed by an
alert physician and lead ultimately to diagnosis usually after
5 years of age, but it may be delayed until the second or third
decades.
Results from our study and review of the literature allow
for distinguishing two types of attenuated MPS VI pheno-
types: osteoarticular and cardiac. It is likely that patients with
osteoarticular symptoms will be found in either rheumatology
or orthopedic clinics. The similarity of attenuated MPS VI to
the more commonly seen rheumatological conditions means
that patients are often misdiagnosed and there is a delay before
the patient’s symptoms are attributed to MPS. Patients with a
cardiac variant of MPS VI are much more probable to be
found in cardiology clinics [18, 19]. In these patients, cardiac
disease progresses silently and ultimately leading to heart
failure and does not correspond with the other typical MPS
features which are very mild or absent [8]. An advanced valve
defect is an indication for valve surgery, which may be ben-
eficial in these patients at an earlier stage of the disease. In
both phenotypes, the pathological process seems to be restrict-
ed at first to one system only, either osteoarticular or cardio-
vascular. In the cardiac phenotype, however, it tends to have
more serious complications leading to fast disease progression
and abrupt death [7].
Despite the utility of communicating with these descriptive
categories, it is important to recognize that the symptoms of
the disease manifested along a continuum. Using a descriptive
classification is very helpful for clinicians; however, it is
important to bear in mind its implications. The term attenuated
(or used by some slowly progressing) implies a slower disease
progression, and it may be perceived that these patients do not
require treatment as urgently as severe patients. The truth is
that these patients may remain asymptomatic for years with
silently (but not necessarily slowly) progressing disease and
be recognized in an advanced disease stage when it is too late
for any intervention [7]. For this reason, we previously sug-
gested using a term cardiac MPS VI variant to add a sense of
urgency as these patients require treatment to be administered
prior to the onset of valve disease [8].
The awareness among cardiologists and rheumatolo-
gists should be raised so they can play an important
role, not only in the management but also in the diag-
nosis of these patients [18]. The extent of cardiac in-
volvement may be underestimated in patients with
mucopolysaccharidosis because of restrictive pulmonary
disease and skeletal abnormalities that limit patients’
activities [19]. We have previously presented a diagnos-
tic algorithm, suggesting uGAG analysis in any patient
with valve disease even in the presence of very mild or
untypical disease symptoms [18]. In cases with a high
index of suspicion such as those with a positive family
history or those with other characteristic features of
MPS VI, enzymatic activity should be determined even
if uGAG excretion is low. As attenuated patients may
still be very difficult to recognize, the delay in diagno-
sis may make it difficult to influence valve disease with
available treatment. Apart from this, we have to bear in
mind that the usefulness of enzyme replacement therapy
is limited due to the fact that a given enzyme prepara-
tion does not have beneficial effects on all aspects of a
disorder in the same degree. The effect of ERT alone on
cardiac structure and function in MPS patients has been
documented in only a few studies [20–23] and larger
studies with longer follow-up are still needed. Addition-
ally, clinical studies have shown that many symptoms of
mucopolysaccharidoses even after long-term treatment
are not anymore reversible. It seems probable that in
the future, a tailored combination therapy using ERT
with novel therapeutic options such as application of
small molecules that either inhibit a key enzyme which
is responsible for substrate synthesis (substrate depriva-
tion) or act as a chaperone to increase the residual
activity of the lysosomal enzyme (enzyme-enhancing
therapy) will be the most effective [24].
By identifying patient’s genotype, it may be possible to
predict the course of the disease and establish more tailored
treatment plan. Patients with the p.Y210C mutation should be
Fig. 2 Pictures of MPS VI patients heterozygous for the p.Y210C
mutation
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covered by a special care team of orthopedists, physiothera-
pists, and rheumatologists with a plan of rehabilitation, proper
early use of orthoses and other support devices, the best
determination of time for bone and joint surgery, and applica-
tion of drug treatments. Patients with the p.R152W should be
referred to a cardiologist before the appearance of symptoms
from the circulatory system. The mechanism why the
p.R152W mutation seems to have a special affinity for the
heart valves remains unknown. Perhaps this stems from the
specific structure of the valves, and each of these mutations
causes different residual enzyme activity. Detecting these
differences would explain the process of affecting different
organs dependent on the flow dynamics of the substrate.
Conclusions
1. Based on the literature review, two types of attenuated
MPS VI phenotypes can be distinguished: osteoarticular
and cardiac, both with a clear genotype–phenotype
correlation.
2. The majority of MPS VI patients reported so far as rela-
tively attenuated presented with an essentially
osteoarticular phenotype associated with p.Y210C muta-
tion in heterozygosity.
3. The term attenuated should be used with caution as it may
imply the slow disease progression and the lack of urgen-
cy to treat these patients.
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